Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Dec 10, 2021 12:58pm
142 Views
Post# 34219187

RE:RE:Nash tag conference

RE:RE:Nash tag conference I think option 4 is the correct answer

Option 4 .....All of the above!!!


SABBOBCAT wrote:

You could look at this in a few ways, 1) they couldnt get a presentation slot because no-one likes them or the unconventional path, 2) MDGL is the lead sponsor and doesnt want to highlight the competition, 3) They are far enough down a partnership path that they dont want need to pay up to market and/or don't want to piss off the new partner by shopping it around further. 

I'd like to think it is option 3, but realistically it is more likely that TH is to cheap to pay for access at these types of events and is unable to drum up the interest to justify an invitation to present.  

 

Bucknelly21 wrote: How can a phase 3 Nash company like Thtx get lost in the mix of 2-3 others?!? They apparently are going to a Nash tag conference in Utah and aren't even presenting? They have a booth lol so embarrassing how much they botched the Nash opportunity 

 

 



<< Previous
Bullboard Posts
Next >>